Reprieve System
Fluid overload in Acute Decompensated Heart Failure (ADHF)
Pilot StudyActive
Key Facts
Indication
Fluid overload in Acute Decompensated Heart Failure (ADHF)
Phase
Pilot Study
Status
Active
Company
About Reprieve Cardiovascular
Reprieve Cardiovascular is a private, pre-revenue medical device innovator targeting the costly and prevalent problem of fluid congestion in heart failure. Its core technology, the Reprieve System, is a personalized intelligent decongestion management platform that provides physicians with real-time feedback and control during diuretic therapy, aiming to optimize fluid removal while mitigating kidney injury risks. The company is currently conducting the FASTR Pilot clinical trial to evaluate its system against standard care and is led by an experienced team with strong venture backing from firms like Arboretum Ventures.
View full company profile